Efficacy and Safety of Traditional Chinese Mecicine Yishen Daluo Yin Granule for Relapsing-remitting Multiple Sclerosis: A Randomized Controlled Trial

The aim of this study is to evaluate the efficacy and safety of YSDLY granule in patients with RRMS. This will be a multi-center, randomized, double-blind, placebo-controlled study.

Start Date15 Mar 2026

Sponsor / Collaborator

Dongzhimen Hospital

[+3]

ITMCTR2026000395

/ SuspendedNot ApplicableIIT

Clinical Efficacy Study of Different Acupuncture Point Selection Schemes in Treating Allergic Rhinitis

Start Date20 Feb 2026

Sponsor / Collaborator

Dongzhimen Hospital

ChiCTR2600116679

/ Not yet recruitingPhase 4IIT

Study on the Efficacy of Shexiang Baoxin Pill in the Treatment of Coronary Microvascular Disease Based on TCM Syndrome Types

Start Date22 Jan 2026

Sponsor / Collaborator

Dongzhimen Hospital

100 Clinical Results associated with Dongzhimen Hospital

0 Patents (Medical) associated with Dongzhimen Hospital

204

Literatures (Medical) associated with Dongzhimen Hospital

01 Feb 2026·EUROPEAN SPINE JOURNAL

Causal relationship between BMI-mediated different modes of transportation and risk of osteoarthritis: a Mendelian randomization and mediation analysis

Article

Author: Xie, Xiaoming ; Zhang, Kuayue ; Lin, Yi ; Li, Xinyi ; Huang, Liangqing ; Tian, Guihua ; Li, Yuan

OBJECTIVE:

The importance of Transport-related Physical Activity in chronic disease management is increasingly recognized. Previous studies have reported relationships between different modes of transportation and the risk of osteoarthritis (OA), but the conclusions across studies have been inconsistent. Body Mass Index (BMI) has been shown to be directly associated with different transportation modes and is also a significant risk factor for OA. Therefore, our study aims to investigate the causal relationship between different modes of transportation and OA, mediated by BMI, using Mendelian randomization (MR) and mediation analysis.

METHODS:

Genome-wide association study (GWAS) data for different transportation modes were extracted from the IEU openGWAS database as exposure data. GWAS summary data for BMI were used as potential mediator variables, and OA data from the IEU openGWAS database were used as outcome data. A two-sample, two-step MR analysis was performed using the Inverse-Variance Weighted (IVW) method to investigate the causal relationships between different modes of transportation and OA, as well as the mediating role of BMI in these associations. Supplementary analyses were conducted using the weighted median method and MR-Egger regression. Cochran's Q test was used to assess heterogeneity among the SNPs, and the MR-Egger intercept test was applied to examine horizontal pleiotropy.

RESULTS:

The MR analysis revealed significant associations between transportation modes and the risk of OA. Cycling (OR = 0.568, 95% CI = 0.325-0.991, P = 0.047), public transportation (OR = 0.584, 95% CI = 0.426-0.802, P = 0.0009), and walking (OR = 0.497, 95% CI = 0.376-0.657, P < 0.0001) were negatively associated with OA risk, whereas driving (OR = 1.19, 95% CI = 1.018-1.385, P = 0.029) was positively associated with OA risk. Mediation analysis indicated that BMI partially mediated the causal relationship between cycling, public transportation, walking, driving, and OA risk, with mediation proportions of 69.6%, 31.9%, 25.0%, and 39.8%, respectively. Cochran's Q test indicated some heterogeneity among the SNPs included in the analysis, and the MR-Egger intercept test suggested no evidence of genetic pleiotropy.

CONCLUSION:

Genetically predicted walking, cycling, or public transportation use was negatively associated with the risk of OA, whereas driving increased the risk of OA. BMI mediated over 25% of the causal relationship between different transportation modes and OA.

CLINICAL TRIAL NUMBER:

Not applicable.

01 Jan 2026·EXPERIMENTAL GERONTOLOGY

Qiliqiangxin capsule improves the cognitive disorders in heart failure rats through regulating blood brain barrier function

Article

Author: Wang, Zhimiao ; Dou, Jinfang ; Gao, Yuqian ; Zhu, Haiyan ; Zhang, Shuai ; Hei, Murong ; Zhao, Hongbing ; Zhao, Yue ; Peng, Jiaran

OBJECTIVE:

This study aimed to investigate the protective effects of Qiliqiangxin capsule (QLQX) against cognitive impairment in rats with heart failure (HF), as well as the underlying mechanisms.

MATERIALS AND METHODS:

Heart failure was induced in rats by LAD ligation. The animals were randomized into four groups (sham, model, QLQX [0.6 g/kg/d], and valsartan [13.3 mg/kg/d]) and received treatment for 60 days. Cardiac function was evaluated by echocardiography, while cognitive function was assessed using the Morris water maze. Myocardial and hippocampal morphology were examined by HE and Nissl staining, respectively. Hippocampal levels of Ang II, Aβ₄₂, and ROS were quantified via ELISA and DHE staining. Finally, Western blot analysis was performed to measure the expression of AT1R, NF-κB, P-gP, RAGE, and the tight junction proteins (Claudin-5, Occludin).

RESULTS:

Echocardiographic assessments revealed that QLQX significantly improved cardiac function in rats with HF-induced cognitive impairment. The Morris water maze test demonstrated that, compared with the model group, QLQX treatment enhanced the targeting of swimming path and increased the number of platform crossings-consistently indicating alleviation of cognitive dysfunction. Histological analysis using HE staining confirmed that QLQX preserved myocardial structural integrity. Nissl staining further demonstrated that QLQX mitigated neuronal damage in the hippocampus. Additionally, QLQX reduced the levels of Ang II, AT1R, ROS, and Aβ_42. It also downregulated the expression of NF-κB and P-gP while upregulating that of Claudin-5 and Occludin.

CONCLUSIONS:

QLQX improves cardiac function and mitigates cognitive decline in rats with heart failure. These protective effects likely involve the reduction of Ang II, AT1R, and ROS levels, alongside inhibition of the NF-κB pathway. Furthermore, QLQX upregulates the tight junction proteins Claudin-5 and Occludin, which helps preserve blood-brain barrier (BBB) integrity. This cascade of events ultimately reduces cerebral Aβ deposition.

31 Dec 2025·ANNALS OF MEDICINE

The efficacy and safety of pilates exercise in patients with knee osteoarthritis: a systematic review with meta-analysis of randomized controlled trials

Review

Author: Yan, Shaoshuai ; Zhang, Wenshuo ; Zhang, Kuayue ; Zhou, Jun ; Ma, Haoning ; Kong, Deming ; Li, Yuan ; Xie, Xiaoming ; Zhao, Fanying

BACKGROUND:

Evidence on the effects of Pilates exercise in patients with knee osteoarthritis (KOA) remains limited. This meta-analysis aimed to evaluate its efficacy and safety.

METHODS:

We searched PubMed, Web of Science, EMBASE, Cochrane Library, and Google Scholar up to May 21, 2024, for randomized controlled trials (RCTs). Outcomes included Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), knee range of motion (ROM), and adverse events. Risk of bias and evidence certainty were assessed; subgroup, sensitivity, and publication bias analyses were performed.

RESULTS:

Eight RCTs involving 322 participants were included. Risk of bias ranged from low to high, mainly due to lack of blinding. Compared to blank controls, Pilates significantly reduced WOMAC scores (SMD = -1.70; 95% CI: -3.14 to -0.25). One study comparing Pilates to health education reported significant reductions in VAS (MD = -1.74; 95% CI: -2.51 to -0.97) and WOMAC (SMD = -1.42; 95% CI: -2.39 to -0.45), but no significant ROM improvement. Compared to other exercises, Pilates showed no significant effects on VAS, WOMAC, or ROM. Funnel plots showed asymmetry for VAS and WOMAC; Egger's test indicated possible publication bias (p = 0.0039 and 0.0154, respectively). No adverse events were reported, but active monitoring was limited. GRADE rated evidence as "very low" for VAS and WOMAC, and "low" for ROM.

CONCLUSION:

Pilates may relieve pain and improve physical function, but has limited effects on ROM. Due to insufficient adverse event reporting, safety remains unclear. Given the low study quality, high heterogeneity, and possible bias, results should be interpreted cautiously. Future studies should use standardized protocols, report long-term adherence, and assess mental health benefits.

News (Medical) associated with Dongzhimen Hospital

19 Jun 2023

·www.prnewswire.com

An Integration of Traditional Chinese Medicine and Modern Medicine Realized by Dongzhimen Hospital of Beijing University of Chinese Medicine

BEIJING, June 19, 2023 /PRNewswire/ -- A news report by haiwainet.cn: Beijing College of Traditional Chinese Medicine (now Beijing University of Traditional Chinese Medicine) and Dongzhimen Hospital, one of its affiliates, cooperated with The Staudinger Company Group in establishing the TCM-Klinik Bad Kötzting, the first licensed TCM hospital in Germany. In terms of patient diagnosis and treatment, the hospital always gives priority to curative effects, and treats patients under the guidance of TCM theories and concepts, showcasing the features and advantages of TCM with successful practices. When it comes to TCM publicity, the hospital has hosted various activities that attracted people in the local area and from neighboring countries, as well as wide coverage by foreign media. In this way, the hospital contributed to the dissemination of TCM overseas. In 2008, the hospital was bestowed with the the 2008 International Award for Contribution to Chinese Medicine, the highest award in the field of international TCM cooperation, by the World Federation of Chinese Medicine Societies (WFCMS). This honor highlighted the great contribution made by the hospital to TCM publicity and education. Promoting the integration of TCM and Modern Medicine Adhering to the concepts of offering patient-centered therapies and combining prevention and treatment, the hospital is committed to safeguarding the health of patients with "the essence in the two schools of medicine", and conducing to the integration of TCM medicine and modern medicine. With regard to exchanges between TCM and Western medicine, the hospital has carried out in-depth discussions with medical institutions worldwide, and co-founded the China-Europe TCM Cooperation and Development Forum with the WFCMS. All these efforts have injected vitality into TCM in its process to become modern and go global. In terms of scientific research on TCM, the hospital has published a total of 156 articles and monographs, and formulated or compiled many standards and other relevant materials, in order to promote standardization in TCM education and research. This also facilitates the integration of TCM and modern medicine. By unremittingly exploring how to integrate TCM and modern medicine and delving deeply into research on TCM, the hospital has emerged as a pioneer in terms of introducing TCM to the world, a bridge for the communication between Chinese and Western cultures, and a contributor to the implementation of the Belt and Road Initiative. SOURCE haiwainet.cn

100 Deals associated with Dongzhimen Hospital

100 Translational Medicine associated with Dongzhimen Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 2

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tianmabianchunzhigan	Dementia, Vascular More	Phase 2
Xinglou Chengqi Granules	Acute Ischemic Stroke More	Phase 2
Acteoside ( AHR x HMGB1 x NLRP3 x PKC x TLR4 )	Diabetic Nephropathies More	Preclinical
CN116253734 ( ACHE x CEL )Patent Mining	Nervous System Diseases More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis